Regeneron shows financial strength and fair valuation, but trevogrumab's Phase 2 progress adds uncertainty. Click here to ...

CHICAGO -- Adding investigational cagrilintide to a GLP-1 receptor agonist increased weight loss in adults with obesity with ...

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in combination with Novo Nordisk's popular obesity drug Wegovy in a mid-stage ...

CHICAGO -- An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in ...

Additional drug combinations may carry a risk of more side effects though, raising concerns from some doctors. Regeneron ...

A new study finds combining bimagrumab with Wegovy leads to significant fat loss without muscle loss. This breakthrough ...

In addition, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) revealed plans to license an experimental obesity drug from China’s Hansoh Pharmaceuticals in a deal valued up to $2.01 billion.

The combination of Regeneron's drug, trevogrumab, and Wegovy helped preserve up to 51.3% of the lean mass after 26 weeks, compared with 34.5% loss when Wegovy was administered alone, advertisement ...

The U.S. Food and Drug Administration has said these drugs need to show additional weight loss or other benefits, such as improvement in patients' strength, to be considered for approval.